

References

I-53

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Bethesda, MD. Update 2012.
2. National Institute for Health and Clinical Excellence (NICE). Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 to 11 years. Technology Appraisal Guidance 133 and 201. London, UK: NICE; April 2013.
3. Maurer, M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med.* 2013;368(10):924-935.
4. Kelmenson D, Kelly V, Winkler T, et al. The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. *Am J Nucl Med Mol Imaging.* 2013;3(4):350–360.
5. Saini S, Bindslev-Jensen C, Maurer M. et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol.* 2015;135(1):67-75.
6. Pasha M, Jourd'heuil D, Jourd'heuil F, et al. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients. *Allergy Asthma Proc.* 2014;35(3):241-9.
7. Chen H, Huang C, Chang E, Kuo H. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. *BMC Pulm Med.* 2016;8;16(1):3.
8. Matin N, Tabatabaie O, Falsaperla F, et al. Efficacy and safety of omalizumab in paediatric age: An update of literature data. *J Biol Reg Homeo Agents.*2016;579-584.
9. Tsabouri A, Tseretopoulou X, Priftis K, et al. Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *AAAAI.* 2014;332-341.
10. Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticarial. *Drug Design, Develop and Ther.* 2015;4909-4915.
11. Urgert MC, van den Elzen, Knulst AC, et al. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment. *Brit Journ Derm.* 2015;404-415.
12. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J.* 201;43(2):343-73.
13. Lin CH, Cheng SL. A review of omalizumab for the management of severe asthma. *Drug Design, Development and Therapy.* 2016;2369-2378.
14. El-Qutob D. Off-Label Uses of Omalizumab. *Clinic Rev Allerg Immunol.* 2016;84–96.
15. Munoz JP, Casado AF, Taboada AC, et al. Successful treatment of refractory idiopathic angio-oedema with omalizumab: review of the literature and function of IgE in angio-oedema. *Clinical and Experimental Dermatology.* 2016;399–402.
16. MICROMEDEX®SOLUTIONS Compendia. 2017. Omalizumab.
17. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2018. Omalizumab.

18. Bhutani M, Yang W, Hebert J, et al. The Real World Effect of Omalizumab Add on Therapy for Patients with Moderate to Severe Allergic Asthma: The ASTERIX Observational Study. *Plos One*. 2017;12(8):1-13.
19. Beck L, Bernstein J, & Maurer M. A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. *Acta Derm Venereol*. 2017;97:149-158.